BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IOV-4001 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of IOV-4001\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05361174-2555@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:IOV-4001: Phase 1/2 readout est. (NCT05361174)
DESCRIPTION:IOV-4001\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in A
 dult Participants With Unresectable or Metastatic Melanoma or Stage III or
  IV Non-small-cell Lung Cancer\nEstimated primary completion: September 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/iov-4001#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05361174
URL:https://assetmemo.bio/drug/iov-4001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
